CorMedix Inc. to be Featured on Panel at FBR & Co. Healthcare Series Event Focused on Infectious Diseases

New Prescriptions: Innovation in the Treatment of Diseases and Infections to be held April 20, 2016 in New York, NY

BEDMINSTER, NJ / ACCESSWIRE / April 6, 2016 / CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced that the Company’s Chief Executive Officer, Randy Milby, will participate in a panel discussion titled, “Showcase of Novel Technologies in Fighting Infections,” as part of FBR & Company’s New Prescriptions: Innovation in the Treatment of Diseases and Infections, on April 20, 2016, in New York.

Randy Milby, CorMedix CEO, said, “We are honored to be invited to participate in this important discussion about novel approaches to fighting infections. Our unique non-antibiotic anti-infective solution Neutrolin® has been proven to reduce bloodstream infections following venous catheter placement, which cost an average of $45,000 per infection and an estimated $2.3 billion annual cost to the U.S. healthcare system. To put it in perspective, this accounts for more than 20% of the total annual cost of hospital-acquired infections. We’ve also demonstrated recently that the active anti-microbial component of Neutrolin, taurolidine, can be effectively incorporated into various medical and surgical materials to prevent infection-related complications and further damage to vulnerable tissues. We are proud of our innovations and look forward to sharing our insights on this panel.”

Please contact your FBR representative for more information. Should you require further information, please contact the FBR Conference and 1on1 Desk (1on1@fbr.com).

About CorMedix Inc.

CorMedix Inc. is an emerging commercial-stage biopharmaceutical company that initiated a Phase III clinical study of a novel anti-infective solution, Neutrolin, in hemodialysis patients in the United States in December 2015. The Company seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of infectious and inflammatory diseases. CorMedix’s first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration, and/or IV medications. The FDA has granted Fast Track status to Neutrolin Catheter Lock Solution and also has designated Neutrolin as a Qualified Infectious Disease Product for oncology, hemodialysis, and critical care/intensive care patients, where catheter-related blood stream infections and clotting can be life-threatening. The initial and planned indications aim to address significant needs in catheter-based treatments in the U.S. and the rest of the world. For more information visit: www.cormedix.com.

For Investors & Media:

CorMedix
Maureen McEnroe, CFA: Maureen@machealthcare.com; (914) 588-1873

Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.: jdrumm@tiberend.com; (212) 375-2664
Janine McCargo: jmccargo@tiberend.com; (646) 604-5150

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects, future financial position, financing plans, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including: the cost, timing and results of the planned Phase 3 trials for Neutrolin® in the U.S.; obtaining additional financing to support CorMedix’s research and development and clinical activities and operations;obtaining regulatory approvals to conduct clinical trials and to commercialize CorMedix’s product candidates, including marketing of Neutrolin in countries other than Europe; the risks associated with the launch of Neutrolin in new markets; CorMedix’s ability to enter into, execute upon and maintain collaborations with third parties for its development and marketing programs; CorMedix’s ability to maintain its listing on the NYSE MKT; the risks and uncertainties associated with CorMedix’s ability to manage its limited cash resources; the outcome of clinical trials of CorMedix’s product candidates and whether they demonstrate these candidates’ safety and effectiveness; CorMedix’s ability to identify and enter into strategic transactions; CorMedix’s dependence on its collaborations and its license relationships; achieving milestones under CorMedix’s collaborations; CorMedix’s dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers, sales and marketing organizations, and consultants; and protecting the intellectual property developed by or licensed to CorMedix. These and other risks are described in greater detail in CorMedix’s filings with the SEC, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

SOURCE: CorMedix Inc.

ReleaseID: 438484